FDA approves Cangene's growth hormone injection

TORONTO, Jan 24 (Reuters) - Cangene Corp (CNJ.TO) said on Thursday that the U.S. Food and Drug Administration has approved its Accretropin recombinant human growth hormone injection.

The company also said that it, along with its development partner Apotex, are assessing current market conditions and patent issues to determine an overall strategy for the product. (Reporting by Scott Anderson; Editing by Peter Galloway)